Delineation of ADPRHL2 Variants : Report of Two New Patients with Review of the Literature
Thieme. All rights reserved..
ADPRHL2 is involved in posttranslational modification and is known to have a role in physiological functions such as cell signaling, DNA repair, gene control, cell death, and response to stress. Recently, a group of neurological disorders due to ADPRHL2 variants is described, characterized by childhood-onset, stress-induced variable movement disorders, neuropathy, seizures, and neurodegenerative course. We present the diagnostic pathway of two pediatric patients with episodic dystonia and ataxia, who later had a neurodegenerative course complicated by central hypoventilation syndrome due to the same homozygous ADPRHL2 variant. We conducted a systematic literature search and data extraction procedure following the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 statement in terms of patients with ADPRHL2 variants, from 2018 up to 3 February, 2023. In total, 12 articles describing 47 patients were included in the final analysis. Median age at symptom onset was 2 (0.7-25) years, with the most common presenting symptoms being gait problems (n = 19, 40.4%), seizures (n = 16, 34%), ataxia (n = 13, 27.6%), and weakness (n = 10, 21.2%). Triggering factors (28/47; 59.5%) and regression (28/43; 60.4%), axonal polyneuropathy (9/23; 39.1%), and cerebral and cerebellar atrophy with white matter changes (28/36; 77.7%) were the other clues. The fatality rate and median age of death were 44.6% (n = 21) and 7 (2-34) years, respectively. ADPRHL2 variants should be considered in the context of episodic, stress-induced pediatric and adult-onset movement disorders and seizures.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Neuropediatrics - (2024) vom: 16. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Öz Yıldız, Sibel [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1055/s-0044-1779618 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368552616 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM368552616 | ||
003 | DE-627 | ||
005 | 20240217232445.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240217s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1055/s-0044-1779618 |2 doi | |
028 | 5 | 2 | |a pubmed24n1297.xml |
035 | |a (DE-627)NLM368552616 | ||
035 | |a (NLM)38365196 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Öz Yıldız, Sibel |e verfasserin |4 aut | |
245 | 1 | 0 | |a Delineation of ADPRHL2 Variants |b Report of Two New Patients with Review of the Literature |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 16.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Thieme. All rights reserved. | ||
520 | |a ADPRHL2 is involved in posttranslational modification and is known to have a role in physiological functions such as cell signaling, DNA repair, gene control, cell death, and response to stress. Recently, a group of neurological disorders due to ADPRHL2 variants is described, characterized by childhood-onset, stress-induced variable movement disorders, neuropathy, seizures, and neurodegenerative course. We present the diagnostic pathway of two pediatric patients with episodic dystonia and ataxia, who later had a neurodegenerative course complicated by central hypoventilation syndrome due to the same homozygous ADPRHL2 variant. We conducted a systematic literature search and data extraction procedure following the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 statement in terms of patients with ADPRHL2 variants, from 2018 up to 3 February, 2023. In total, 12 articles describing 47 patients were included in the final analysis. Median age at symptom onset was 2 (0.7-25) years, with the most common presenting symptoms being gait problems (n = 19, 40.4%), seizures (n = 16, 34%), ataxia (n = 13, 27.6%), and weakness (n = 10, 21.2%). Triggering factors (28/47; 59.5%) and regression (28/43; 60.4%), axonal polyneuropathy (9/23; 39.1%), and cerebral and cerebellar atrophy with white matter changes (28/36; 77.7%) were the other clues. The fatality rate and median age of death were 44.6% (n = 21) and 7 (2-34) years, respectively. ADPRHL2 variants should be considered in the context of episodic, stress-induced pediatric and adult-onset movement disorders and seizures | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Yalnızoğlu, Dilek |e verfasserin |4 aut | |
700 | 1 | |a Şimsek Kiper, Pelin Özlem |e verfasserin |4 aut | |
700 | 1 | |a Göçmen, Rahşan |e verfasserin |4 aut | |
700 | 1 | |a Soğukpınar, Merve |e verfasserin |4 aut | |
700 | 1 | |a Utine, Gülen Eda |e verfasserin |4 aut | |
700 | 1 | |a Haliloğlu, Göknur |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Neuropediatrics |d 1993 |g (2024) vom: 16. Feb. |w (DE-627)NLM012996483 |x 1439-1899 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:16 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0044-1779618 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 16 |c 02 |